This approval is based on robust evidence from the SOUL cardiovascular outcomes trial, which demonstrated that oral semaglutide significantly lowers cardiovascular risk, even in patients who have not previously experienced a cardiovascular event
Discussions typically include dosing strategies, duration of therapy, and regulatory considerations, as these peptides are not FDA-approved for all uses and may be considered investigational
Promoting fat loss Many patients experience a significant reduction in stubborn fat deposits
Schedule a consultation today to explore evidence-based weight management solutions designed for lasting success
(, , (), ) (
In a public advisory on Wednesday, Health Canada said that as interest grows in GLP-1 products for weight loss, "some people may turn to unauthorized or counterfeit products, which could pose serious health risks because they have not been assessed by Health Canada for safety, effectiveness, or quality." The versions of the medications authorized for use in Canada are semaglutide (Ozempic and Wegovy injections and Rybelsus oral tablets) and tirzepatide (Mounjaro and Zepbound injections)
